BioSim™ anti-Golimumab (Simponi®) (Human) ELISA Kit

Golimumab (Simponi®) is a human immunoglobulin G1κ monoclonal antibody which is specific for pro-inflammatory cytokine, tumor necrosis factor-α (TNFα). Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF and prevent TNF from binding to its receptors and finally inhibits biological activity of TNF. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Golimumab ELISA kit is designed to detect the antibody against Golimumab with high specificity and sensitivity in biological matrices.

Alternate Name: N/A

Tag Line: A Sandwich ELISA kit for the qualitative determination of antibody against Golimumab in human serum or plasma.

Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- qualitative determination of antibody against Golimumab (Simponi) in human serum and plasma

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: This ELISA kit is used for Qualitative determination of antibody against Golimumab (Simponi) in serum and plasma

Features & Benefits: Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Golimumab (Simponi) in human serum and plasma. Cross Reactivity: Golimumab (Simponi) infusion camouflages/masks the presence of antibody to Etanercept (ATC) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATC. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Golimumab.